Kezar Life Sciences, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 188.4K | $1.40M | 0.00% | Added+43.5% | 2026-03-31 |
| StateStreet | passive | 27.1K | $201.03K | 0.00% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 10.2K | $75.74K | 0.00% | Added+4807.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.91 | — | — |
| 2026-05-11 | -0.98 | -0.70 | +28.53% |
| 2026-03-27 | -1.31 | -1.05 | +19.57% |
| 2025-11-12 | -1.96 | -1.53 | +21.81% |
| 2025-08-13 | -2.32 | -1.87 | +19.54% |
| 2025-05-13 | -2.60 | -2.00 | +23.03% |
| 2025-03-25 | -2.76 | -3.00 | -8.70% |
| 2024-11-12 | -3.17 | -2.78 | +12.21% |
| 2024-08-13 | -3.10 | -2.75 | +11.15% |
| 2024-05-09 | -3.10 | -3.00 | +3.23% |
| 2024-03-14 | -3.90 | -3.58 | +8.09% |
| 2023-11-13 | -3.55 | -3.20 | +9.86% |
| 2023-08-10 | -3.35 | -3.40 | -1.49% |
| 2023-05-11 | -2.90 | -3.10 | -6.90% |
| 2023-03-14 | -2.85 | -2.50 | +12.28% |
| 2022-11-10 | -2.70 | -2.50 | +7.41% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| KZR | -0.55% | +2.68% | +15.90% | +74.40% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.51% | +7.31% | +19.34% | +61.71% |